Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AveXis, Inc. (NASDAQ: AVXS).

Full DD Report for AVXS

You must become a subscriber to view this report.

Recent News from (NASDAQ: AVXS)

PTC Therapeutics Surges On Positive Outcome From Rare Disease Study
Recently, PTC Therapeutics ( PTCT ) announced that it had obtained positive results from a phase 1 trial treating patients with spinal muscular atrophy ((SMA)). The results do not only hold up against competitors, but could now possibly put this treatment at the top for this disease. Conside...
Source: SeekingAlpha
Date: June, 19 2018 04:45
Crispr On Hold While Sangamo Accelerates
We're at a key point when it comes to cell and gene therapy. These therapies have the potential to address hundreds, if not thousands, of different rare and common diseases. For a long time, they were largely theoretical constructs. Now they're a therapeutic reality. And it's my expectation ...
Source: SeekingAlpha
Date: June, 04 2018 15:21
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher
Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market ...
Source: SeekingAlpha
Date: May, 31 2018 16:08
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined...
Source: SeekingAlpha
Date: May, 15 2018 14:48
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Our Free Research Report on Biogen and More Biotech Stocks
Stock Research Monitor: AVXS, BHVN, and BMRN LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on BIIB sign up now at . On Tuesday, May 08, 2018, US markets saw four out of nine sectors finishing the day in green, four in re...
Date: May, 09 2018 07:35
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37
AveXis misses by $2.88
AveXis (NASDAQ: AVXS ): Q1 EPS of -$6.20 misses by $2.88 . Cash and cash equivalents of $586.8M Press Release More news on: AveXis, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 03 2018 16:47


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AVXS.

About AveXis, Inc. (NASDAQ: AVXS)

Logo for AveXis, Inc. (NASDAQ: AVXS)

Not available


Contact Information



Current Share Structure

  • Market Cap: $8,019,732,967 - 05/14/2018
  • Issue and Outstanding: 36,816,476 - 05/03/2018


Recent Filings from (NASDAQ: AVXS)

Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 17 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 16 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: May, 15 2018
Amendment to a previously filed SC 14D9
Filing Type: SC 14D9/AFiling Source: edgar
Filing Date: May, 15 2018
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Filing Type: 25-NSEFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: May, 15 2018
Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: May, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018



Daily Technical Chart for (NASDAQ: AVXS)

Daily Technical Chart for (NASDAQ: AVXS)

Stay tuned for daily updates and more on (NASDAQ: AVXS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AVXS)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVXS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AVXS and does not buy, sell, or trade any shares of AVXS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: